Related Experiment Video

Updated: Jun 22, 2026

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
19:44

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

Discovery of a novel proteasome inhibitor selective for cancer cells over non-transformed cells

Aslamuzzaman Kazi1, Harshani Lawrence, Wayne C Guida

  • 1Drug Discovery Department, Moffitt Cancer Center, Tampa, FL 33612, USA.

Cell Cycle (Georgetown, Tex.)
|May 28, 2009
PubMed

Insights

A novel compound, PI-083, selectively targets cancer cells by inhibiting proteasome activity, showing greater efficacy and fewer side effects than Bortezomib. This discovery offers a promising new avenue for cancer therapeutics.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Cancer Research

Background:

  • The ubiquitin/proteasome system is crucial for regulating proteins involved in cell cycle, apoptosis, and angiogenesis, making it a key target for cancer therapeutics.
  • Existing proteasome inhibitors, like Bortezomib, face challenges with selectivity and side effects.

Purpose of the Study:

  • To identify novel proteasome inhibitors with improved selectivity for cancer cells.
  • To characterize the efficacy and selectivity of a newly discovered inhibitor, PI-083.

Main Methods:

  • In silico screening and experimental validation of compounds from NCI chemical libraries.
  • Molecular docking to predict binding interactions of PI-083 with proteasome subunits.
  • In vitro assays measuring chymotrypsin-like (CT-L) activity, cell proliferation, and apoptosis in cancer and normal cell lines.
  • In vivo studies using nude mouse xenografts to assess tumor growth suppression.
  • Analysis of CT-L activity in tumor and liver tissues post-treatment.

Main Results:

  • PI-083 was identified as a potent inhibitor of proteasome CT-L activity.
  • Molecular docking revealed specific interactions of PI-083 with proteasome beta5 and beta6 subunits.
  • PI-083 demonstrated selective inhibition of proliferation and induction of apoptosis in various cancer cells compared to normal cells.
  • PI-083 exhibited faster and more potent antitumor effects in vitro and in vivo than Bortezomib.
  • PI-083 showed selective inhibition of tumor CT-L activity without affecting liver CT-L activity, unlike Bortezomib.

Conclusions:

  • PI-083 is a highly selective proteasome inhibitor with significant antitumor potential.
  • Its superior selectivity and efficacy suggest PI-083 may offer a safer and more effective cancer therapeutic option.
  • Further preclinical studies are warranted to advance PI-083 towards clinical application.

More Related Videos

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer10:46

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

A Fluorescence-based Protocol for Preliminary Screening of Protein Synthesis Inhibitors from Natural Sources10:24

A Fluorescence-based Protocol for Preliminary Screening of Protein Synthesis Inhibitors from Natural Sources

Published on: January 27, 2026

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...